Skip to content
OpenCapital
Get started

Neuropace, Inc. NPCE Q2 2025 earnings

Reported August 12, 2025 · After market close

Revenue$23.5MMiss by $913.1KDiluted EPS-$0.26Miss by $0.02
Revenue estimate$24.4M
EPS estimate-$0.24

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$22.6M
EPS estimate-$0.19

Financials

Q2 2025

Income statement

See full
Revenue$23.5M+22.1%
Gross profit$18.1M+28.3%
Operating income-$6.8M-9.5%
Net income-$8.7M-15.1%
EPS (diluted)-$0.260.0%

Balance sheet

See full
Cash & equivalents$23.0M+77.2%
Total debt$71.5M-2.9%
Total equity$19.4M+96.6%
Total assets$106.1M+12.4%

Cash flow

See full
Operating cash flow-$2.1M+46.5%
CapEx$168.0K+167%
Free cash flow-$2.3M+43.1%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$352.91M+65.0%
Enterprise value$401.45M+46.2%
P/S4×+1.0×

Profitability

See full
Gross margin75.7%+1.6pp
Operating margin-22.4%-5.8pp
Net margin-29.3%-6.7pp
FCF margin-18.6%-3.5pp

Returns & leverage

See full
Return on equity-176.9%-13.0pp
Debt / equity3.7×-3.8×
Current ratio5.5×-0.9×

Versus estimates

Revenue

Q1 2026$22.0MBeat by $355.4KQ4 2025$26.6MBeat by $1.8MQ3 2025$27.4MBeat by $2.3M
Q2 2025$23.5MMiss by $913.1K
Q1 2025$22.5MMiss by $186.3KQ4 2024$21.5MMiss by $93.9K

Diluted EPS

Q1 2026-$0.13Beat by $0.06Q4 2025-$0.08Beat by $0.06Q3 2025-$0.11Beat by $0.09
Q2 2025-$0.26Miss by $0.02
Q1 2025-$0.21Beat by $0.05Q4 2024-$0.18Beat by $0.07

Ask the moment Neuropace, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Neuropace, Inc. report Q2 2025 earnings?
Neuropace, Inc. (NPCE) reported Q2 2025 earnings on August 12, 2025 after market close.
What were Neuropace, Inc.'s Q2 2025 revenue and EPS?
Neuropace, Inc. reported revenue of $23.5M and diluted EPS of $-0.26 for Q2 2025.
Did Neuropace, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $24.4M by $913.1K. EPS missed the consensus estimate of $-0.24 by $0.02.
How did Neuropace, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 22.1% from $19.3M a year earlier and diluted EPS grew 0.0% from $-0.26.
Where can I find Neuropace, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001528287-25-000022) directly on SEC EDGAR. The filing index links above go to sec.gov.